SEATTLE

,

March 2, 2022

/PRNewswire/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at

1:30 p.m. ET

. The conference will be held in a virtual meeting format.

Presentation details:

Event: Cowen 42

^nd

Annual Healthcare Conference

Date:

Monday, March 7, 2022


Time:

1:30 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at

www.ctibiopharma.com

.

About CTI BioPharma Corp.


We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO

^TM

(pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10

⁹

/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO

^TM

is a trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:


Argot Partners

+212-600-1902


[email protected]

View original content to download multimedia:

https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-cowen-42nd-annual-healthcare-conference-301494288.html

SOURCE CTI BioPharma Corp.